Table 5 iPSCs for developing immunotherapies for cancer
From: Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy
Cancer Type | In vitro Model of Cancer Cells | Immune Response Observed | Comparison with Traditional Cancer Cell Lines | References |
|---|---|---|---|---|
Breast Cancer | 3D organoid culture | Enhanced tumor antigen presentation and T cell activation | Better recapitulation of tumor microenvironment and cellular heterogeneity | |
Lung Cancer | Co-culture with immune cells | Increased production of cytotoxic T lymphocytes (CTLs) and cytokines | Improved immune checkpoint inhibitor screening and drug development | |
Colorectal Cancer | Patient-derived tumor spheroids | Enhanced infiltration and activation of NK cells | Better representation of tumor-stromal interactions and drug sensitivity | |
Melanoma | 2D and 3D melanoma models | Induction of tumor-specific CD8 + T cell response | Accurate modeling of immune evasion and resistance mechanisms | |
Prostate Cancer | Tumor-stroma co-culture system | Augmented tumor-associated macrophage polarization and cytokine secretion | Improved understanding of tumor-immune cell crosstalk and therapeutic targeting | |
Leukemia | Hematopoietic differentiation | Generation of functional NK cells for adoptive cell therapy | Enhanced scalability and standardized production of immune effector cells | |
Pancreatic Cancer | Pancreatic tumor organoids | Activation of tumor-infiltrating lymphocytes (TILs) and increased cytotoxicity | Recapitulation of tumor architecture and drug screening using patient-specific iPSCs | |
Ovarian Cancer | 3D tumor spheroids | Enhanced infiltration and activation of DCs | Improved study of antigen presentation and personalized immunotherapy | |
Brain Cancer | Glioblastoma multiforme (GBM) organoids | Immune checkpoint blockade-induced tumor regression | More reliable testing of immune checkpoint inhibitors and personalized treatment strategies | |
Gastric Cancer | Co-culture with tumor-associated fibroblasts (TAFs) | Modulation of myeloid-derived suppressor cells (MDSCs) and improved anti-tumor immune response | Better understanding of tumor-stromal interactions and therapeutic resistance mechanisms | |
Lymphoma | Hematopoietic differentiation | Generation of CAR T cells for targeted therapy | Scalable production of CAR T cells from patient-specific iPSCs | |
Bladder Cancer | Bladder cancer cell line co-culture | Induction of tumor-specific CD4 + T helper cell response | Accurate modeling of immune evasion and immunosuppressive mechanisms | |
Pancreatic Cancer | Patient-derived pancreatic tumor organoids | Activation of tumor-specific CD4 + and CD8 + T cells | Better representation of tumor heterogeneity and drug response | |
Sarcoma | 3D scaffold-based tumor models | Increased infiltration and activation of TILs | Improved understanding of immune evasion mechanisms in sarcoma | |
Liver Cancer | Liver tumor organoids | Enhanced NK cell cytotoxicity against cancer cells | Better recapitulation of liver tumor microenvironment and drug screening | |
Head and Neck Cancer | Co-culture with oral epithelial cells | Induction of anti-tumor immune response through enhanced antigen presentation | Study of immune escape mechanisms and development of targeted therapies | [453] |
Bone Cancer | Osteosarcoma tumor spheroids | Activation of osteoclasts and osteoblasts for bone remodeling and immune cell interaction | Improved understanding of bone metastasis and novel immunotherapeutic targets | |
Esophageal Cancer | 3D esophageal organoids | Generation of tumor-specific CTLs for adoptive cell therapy | Accurate modeling of tumor-stromal interactions and drug response in esophageal cancer | |
Prostate Cancer | Prostate tumor organoids | Activation of tumor-specific CD4 + T helper cells and CD8 + CTLs | Better representation of tumor heterogeneity and drug screening | |
Brain Cancer | Glioblastoma stem cell culture | Enhanced infiltration of immune effector cells and increased cytokine production | Improved understanding of the tumor microenvironment and immunomodulation | |
Cervical Cancer | Co-culture with cervical epithelial cells | Induction of tumor-specific CD8 + T cell response and cytotoxicity | Enhanced study of human papillomavirus (HPV)-related immune responses | [464] |
Bone Marrow Cancer | Hematopoietic differentiation | Generation of functional NK cells and DCs for immunotherapy | Scalable production of immune effector cells with desired functionalities | |
Liver Cancer | 3D liver tumor organoids | Enhanced activation of tumor-infiltrating lymphocytes (TILs) and immune checkpoint modulation | Improved mimicry of liver tumor microenvironment and drug response | |
Thyroid Cancer | Thyroid tumor spheroids | Induction of tumor-specific antibody production by B cells | Study of tumor-immune cell interactions and antibody-based therapies |